Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKF-310 Phase 1 SAD in healthy male volunteers
NCT02695004Phase 1Completed
- Sponsor
- Dongkook Pharmaceutical
- Start
- Feb 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DKF-310 in Alzheimer's disease (AD) (5 arms), sponsored by Dongkook Pharmaceutical. Primary endpoints: Area Under the Curve at 1056 hours and Maximum Concentration at 1056 hours. Started Feb 2016; status: completed.
02
Drugs
DKF-310
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02695004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02695004.